EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
Cancer Research and Treatment. 2023;55(2):498-505 
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress
Clinical Lung Cancer. 2021;22(4):371-375
THE EFFECT OF EGFR MUTATION TO METASTASIS IN STAGE III-IVB LUNG ADENOCARCINOMA
Respirology. 2018;23:283-283
Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series
Frontiers in Oncology. 2022;12:
The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
OncoTargets and Therapy. 2017;Volume 10:2335-2340
Concurrent carboplatin (CBDCA) and Radiotherapy (RT) for unresectable stage III Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer. 1991;7:159
Whole brain radiotherapy (WBRT) for surgically unresectable brain metastasis in pretreated patients with extensive stage small cell lung cancer (ES-SCLC)
Lung Cancer. 2020;139:S65
PREVENTING AND TREATING BRAIN METASTASES WITH THREE FIRST-LINE EGFR-TYROSINE KINASE INHIBITORS IN PATIENTS WITH EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER
Respirology. 2018;23:285-285
Preoperative chemoradiotherapy for stage III unresectable non-small cell lung cancer: Results of a phase II study
Lung Cancer. 1996;16(1):127
Concurrent carboplatin (CBDCA) and radiotherapy (RT) for unresectable stage III (Mo) non-small cell lung cancer (NSCLC)
Lung Cancer. 1994;10:S335-S336